Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen

ConclusionsOverall, dulaglutide was generally well tolerated and improved glycemic control significantly versus placebo, regardless of insulin regimen.Trial RegistrationClinicalTrials.gov identifier, NCT02750410.

Source: Diabetes Therapy - January 28, 2020 Category: Endocrinology Source Type: research